Podcast: USP's Tina Morris on New Biologics Chapters - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Podcast: USP's Tina Morris on New Biologics Chapters


USP's Tina Morris on Biologics Standards

Vice-president for biologics and biotechnology, US Pharmacopeia's Tina Morris discusses plans for new monoclonal antibody chapters, a product-class approach, the need for industry input, efforts toward pharmacopeial harmonization, and more. Recorded LIVE at the USP 2011 Science and Standards Symposium, October 2011.
Interviewed by Angie Drakulich, senior managing editor.

Related podcast with USP's Matthew van Hook

Related podcast with Gillian Woollet

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here